

7/10/03

C. Stye

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Kazuo KUBO, et al.

SERIAL NO: 09/889,858

FILED: July 23, 2001

FOR: QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES



AU: 1624

EXAMINER: Mark L. Berch

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

This is a request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above-identified application.

Submission required under 37 C.F.R. §1.114

RECEIVED

JUL 03 2003

TECH CENTER 1600/2900

Previously Submitted:

- ☐ Consider the amendment(s)/reply under 37 C.F.R. §1.116 previously filed on
- ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on

Enclosed:

- ☒ Amendment/Reply
- ☐ Information Disclosure Statement (IDS)
- ☒ Other: Request for Extension of Time (three months)

FEES	RATE	CALCULATIONS
<input type="checkbox"/> Suspension of action on the above-identified application is requested under 37 C.F.R. §1.103(c) for a period of _____ months.	\$130.00	\$0.00
<input checked="" type="checkbox"/> RCE Fee required under 37 C.F.R. §1.17(e)	\$750.00	\$750.00
<input checked="" type="checkbox"/> A THREE MONTH EXTENSION OF TIME IS REQUESTED		\$930.00
<input type="checkbox"/>		\$0.00
TOTAL OF ABOVE CALCULATIONS:		\$1,680.00
<input type="checkbox"/> REDUCTION BY 50% FOR FILING AS SMALL ENTITY		\$0.00
TOTAL:		\$1,680.00

- ☒ A check in the amount of \$1,680.00 is enclosed
- ☒ Please charge any additional Fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- ☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 CFR 1.136, and any additional fees required under 37 CFR 1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate of this sheet is enclosed.

07/01/2003 CCHAUI 00000167 09889858

01 FC:1801

750.00 0P

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Thomas W. Barnes III, Ph.D.


Registration No. 52,595



22850

Customer Number 22850
Tel. (703) 413-3000
Fax. (703) 413-2220

DOCKET NO.: 221969US0PCT



#19/C
7/10/03
C. Stiles

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
KAZUO KUBO, ET AL. : EXAMINER: BERCH, M. L.
SERIAL NO: 09/889,858 :
FILED: JULY 23, 2001 : GROUP ART UNIT: 1624
FOR: QUINOLINE DERIVATIVES AND :
QUINAZOLINE DERIVATIVES :

AMENDMENT AND REQUEST FOR RECONSIDERATION

RECEIVED

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

JUL 03 2003

TECH CENTER 1600/2900

SIR:

Responsive to the Official Action dated December 31, 2002 Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks. Further, Applicants file herewith a Request for Continued Examination.

IN THE CLAIMS

Please cancel Claims 1-48 and 51-59 without prejudice.

Please add the following claims.

C' --60. (New) A compound, wherein said compound has at least one chemical name selected from the group consisting of N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)-oxy]phenyl}-N'-propylurea, N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-N'-ethylurea, N-butyl-N'-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}urea, N-{2-